Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | PGR | P06401 | 6/20 | 0.52 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | BAX | Q07812 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310443 | 0.92 | SMN1; SMN2 (0.61) | TSHRSMN1; SMN2PGRKDM4ELMNA | |
| SCHEMBL29566488 | 0.83 | TSHR (0.56) | TSHRSMN1; SMN2PGRKDM4ELMNA | |
| SCHEMBL24309299 | 0.83 | TSHR (0.56) | TSHRSMN1; SMN2PGRKDM4ELMNA | |
| SCHEMBL26810953 | 0.81 | TSHR (0.48) | TSHRSMN1; SMN2PGRCYTH2KDM4E | |
| SCHEMBL26806813 | 0.81 | MAPT (0.61) | TSHRSMN1; SMN2PGRKDM4ELMNA | |
| SCHEMBL24309617 | 0.80 | TSHR (0.55) | TSHRSMN1; SMN2PGRKDM4ELMNA | |
| SCHEMBL24309977 | 0.80 | TSHR (0.52) | TSHRSMN1; SMN2PGRCYTH2KDM4E | |
| SCHEMBL24310547 | 0.79 | MAPT (0.50) | TSHRSMN1; SMN2PGRCYTH2ALDH1A1 | |
| SCHEMBL26811027 | 0.79 | TSHR (0.51) | TSHRSMN1; SMN2PGRCYTH2KDM4E | |
| SCHEMBL26811032 | 0.78 | TSHR (0.50) | TSHRSMN1; SMN2PGRKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | TSHR 1755/4885SMN1; SMN2 4847/4885PGR 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.